BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Hasco Medical, Inc. (HASC) Announces Record Quarterly Profit and Sales


8/14/2012 10:29:24 AM

ADDISON,Texas, Aug. 13, 2012 /PRNewswire/ -- HASCO Medical, Inc. (OTCBB: HASC), www.HascoMed.com, a Company that conducts sales of handicap accessible vans, parts, service and rental operation in sixteen locations from Maine to Florida and sales of medical equipment and supplies in Alabama, Florida and Mississippi, announced today their second quarter profit and sales results.

HASCO Medical, Inc.'s Q2 profit increased to approximately $202,957 from a loss of $(37,691) last year. That is a significant increase from Q1 which increased to $51,650 this year from a loss of $(155,656) last year. This puts HASCO Medical, Inc. at a total year-to-date profit through June of $254,607 vs. a loss of $(193,398) last year for the same period.

HASCO Medical, Inc. had the same outstanding results on its top line sales volume. Q2 sales increased to $19.7 million this year from $1.9 million last year. That is another impressive increase from Q1 this year which increased to $8,825,230 vs. $484,329 last year. The total top line sales year-to-date through June increased $38.3 million from $2.3 million last year.

"We are beginning to see the synergies and benefits of our growth through the acquisition of Mobility Freedom in May 2011 and Ride-Away in March of this year. We have worked to put in place programs and Team Members to increase accountability and profitability in our operations," stated Hal Compton, CEO of HASCO Medical, Inc. "I am encouraged by the fact that we were able to see the financial results of these programs so quickly as you can see from our Q1 to Q2 results."

About HASCO Medical, Inc.
HASCO Medical ("HASC" or the Company) provides products and services that dramatically improve the quality of living for its customers. The Company now consists of Ride-Away, Mobility Freedom, Wheelchair Vans of America and Certified Auto on the Van Conversion/Rental side and Southern Medical and Mobility, Inc. and Certified Medical on the DME side.

This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify those so-called "forward looking statements" by words such as "may," "will," "should," "expects," "plans," "targets," "believes," "anticipates," "estimates," "predicts," "potential," or "continue" or the negative of those words and other comparable words. These forward looking statements are subject to risks and uncertainties, product tests, commercialization risks, availability of financing and results of financing efforts that could cause actual results to differ materially from historical results or those anticipated. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC, which are available on its website at: http://www.sec.gov. We assume no obligation to update or alter our forward-looking statements made in this release or in any periodic report filed by us under the Securities Exchange Act of 1934 or any other document, whether as a result of new information, future events or otherwise, except as otherwise required by applicable federal securities laws.

Investor Contact:
MCG LLC
407-333-1255
investorinfo@morganconsultinggroup.net

SOURCE HASCO Medical, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES